TacticScaleWhat Cooper Companies Does & How It Makes Money (COO)
Updated October 2026 · reflects Cooper Companies's latest reported financials
Maker of contact lenses and women's health and fertility products. It makes money by selling contact lenses, medical devices, and fertility consumables and equipment to distributors, eye care and health care professionals, retailers, hospitals and clinics.
How Cooper Companies makes money
It makes money by selling contact lenses, medical devices, and fertility consumables and equipment to distributors, eye care and health care professionals, retailers, hospitals and clinics. It also charges for services such as genetic testing, donor gamete services, and cord blood and cord tissue storage.
What Cooper Companies does
The Cooper Companies runs two businesses. CooperVision makes spherical, toric and multifocal contact lenses for everyday vision problems such as nearsightedness, astigmatism and presbyopia. CooperSurgical focuses on family and women's health. It sells fertility products and services, medical devices and contraception, including the hormone-free Paragard IUD, and offers donor gamete services, genetic testing, and cord blood and cord tissue storage. Cooper sells through distributors, group purchasing organizations, independent eye care practices, corporate retailers, hospitals, clinics and authorized resellers. Founded in 1958, it is headquartered in San Ramon, California.
Products & services
- CooperVision spherical, toric and multifocal contact lenses
- Paragard hormone-free IUD
- Fertility consumables and equipment
- Donor gamete services
- Genetic testing services
- Cord blood and cord tissue storage
What is Cooper Companies worth?
On an owner-earnings DCF, Cooper Companies's most-likely value is about $82 versus a recent price near $54 (50% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$40) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
STAAR Surgical (STAA) · Cofoe Medical Technology (301087.SZ) · Coherent (COHR) · Eyebright Medical Technology (Beijing) (688050.SS) · Glaukos (GKOS)